Monoclonal gammopathy of undetermined significance: Using risk stratification to guide follow-up.
Varying combinations of 3 measurable factors determine a patient's risk of progressing toward multiple myeloma and influence monitoring decisions. This review--and accompanying algorithm--can guide your approach. For monoclonal gammopathy of undetermined significance (MGUS) patients at low risk, repeat serum protein electrophoresis (SPE) in 6 months. If no significant elevation of M-protein is found, repeat SPE every 2 to 3 years.
Northeast Ohio Medical University, Rootstown, OH, USA.
Zia
Z
Uddin
Northeast Ohio Medical University, Rootstown, OH, USA.
Diane
D
Maennle
Northeast Ohio Medical University, Rootstown, OH, USA.
Kimberly
K
Russell
Northeast Ohio Medical University, Rootstown, OH, USA. Email: jboltri@neomed.edu.
John M
JM
Boltri
D001797:Blood Protein Electrophoresis; D064211:Connectin / Q000032:analysis; D018450:Disease Progression; D006801:Humans; D008297:Male; D008875:Middle Aged; D008998:Monoclonal Gammopathy of Undetermined Significance / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy; D015995:Prevalence; D018570:Risk Assessment
D064211:Connectin